Vetoquinol's Sales Performance as of September 2024
At the conclusion of September 2024, Vetoquinol (Paris: VETO) reported impressive sales figures totaling €398 million. This reflects a growth of +1.6% when noted on a reported basis and an increase of +1.8% when accounting for constant exchange rates. Over this period, Vetoquinol faced net negative currency impacts amounting to €-1 million primarily linked to the Americas and Asia Pacific/Rest of World regions. However, these were partially offset by a positive currency impact of €1.4 million attributed to the European market.
Essential Products Contribution
Significantly, the sales from essential products hit €241 million. This represents a commendable growth of +3.9% as reported and similarly at constant exchange rates. By September 30, 2024, essential products made up 61% of the total sales for the laboratory, marking an increase from 59% during the same time in 2023.
Geographic Performance Overview
In terms of strategic territories, sales in Europe and Asia-Pacific/Rest of World demonstrated steady growth, with increases of +3.6% and +12.3%, respectively. However, the United States market faced a decline of -11.5%. This decrease is attributed to previously mentioned issues from the presentation of the Half-Year Results 2024, particularly a decrease in inventories among American wholesalers and the temporary unavailability of certain products. Excluding the United States, the Americas territory observed a robust increase of +7.6%.
Sales by Animal Category
Evaluating further into product categories, Vetoquinol reported sales of €281 million for companion animal products, which saw a growth of 1.6% at constant exchange rates. These sales accounted for 70.4% of the total sales, demonstrating the company’s significant focus on this segment. On the other hand, sales for farm animals were reported at €117 million, which increased by +2.0% when examined at constant exchange rates.
Quarterly Insights
In the third quarter of FY 2024, Vetoquinol's sales reached €134 million, which remained stable with a slight decrease of -0.5% at constant exchange rates. The foreign exchange scenario had a negative impact of €1 million (-1.0%), significantly affecting the Americas region excluding the United States. Notably, the laboratory's cash position exhibited improvement throughout the third quarter.
Future Expectations
While the sales for the first nine months of 2024 remain unaudited by the Statutory Auditors, stakeholders are eagerly anticipating future publications. The next significant announcement regarding annual sales is expected on January 30, 2025, after market close.
About Vetoquinol
Founded in 1933, Vetoquinol has emerged as a notable independent player in the animal health sector, operating extensively across Europe, the Americas, and Asia/Pacific. The company focuses on the innovation, development, and marketing of veterinary medicines, as well as non-medicated products for both farm animals, such as cattle and pigs, and pets, including dogs and cats. Vetoquinol’s commitment to expanding its product portfolio and pursuing strategic acquisitions in high-potential regions has contributed to its hybrid growth model. As of June 30, 2024, the company employed a workforce of 2,519 individuals.
Conclusion and Forward-Looking Indicators
Vetoquinol continues to guide its growth trajectory through strong product offerings and regional expansions. The company's focus on essential products is evidently paying off. As Vetoquinol seeks to maintain this growth momentum, it is poised to harness its broad market reach and innovative capabilities to remain competitive in animal health.
Frequently Asked Questions
What were Vetoquinol's total sales by September 2024?
Vetoquinol's sales totaled €398 million by the end of September 2024.
How did essential products perform in sales?
Sales of essential products reached €241 million, growing by +3.9% on a reported basis.
What challenges did Vetoquinol face in the U.S. market?
The U.S. market encountered a decline of -11.5% due to inventory reductions and product availability issues.
What percentage of Vetoquinol's sales are from companion animals?
Sales from companion animals accounted for 70.4% of Vetoquinol’s total sales in this reporting period.
What is Vetoquinol's focus for future growth?
Vetoquinol aims to enhance its essential products and expand its market presence through strategic acquisitions and innovations.
